Adalimumab: A Review in Chronic Plaque Psoriasis

Drugs

Volumn 75, Issue 18, 2015, Pages 2119-2130

  Burness, Celeste B ^a   McKeage, Kate ^a  

^a Springer Mairangi Bay ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO; ANTIINFLAMMATORY AGENT;

ADULT; ALLERGIC REACTION; ARTICLE; CHILD; CHRONIC DISEASE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; GROUPS BY AGE; HUMAN; INFECTION; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT WITHDRAWAL; ADOLESCENT; PATHOLOGY; PSORIASIS; SEVERITY OF ILLNESS INDEX;

ADALIMUMAB; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84948970785     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0503-x     Document Type: Article

References (75)

1. National Psoriasis Foundation. Psoriasis overview and psoriasis statistics. 2015. https://www.psoriasis.org/. Accessed 15 Oct 2015.
2. Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373-84.
3. Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983-94.
4. NICE. Psoriasis: the assessment and management of psoriasis (NICE guidelines [CG153]). 2012. http://www.nice.org.uk/guidance/cg153. Accessed 15 Oct 2015.
5. European Dermatology Forum (EDF). European S3-guidelines on the systemic treatment of psoriasis vulgaris: update 2015. 2015. http://www.euroderm.org/edf/. Accessed 13 Oct 2015.
6. de Oliveira MF, de Rocha BO, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9-20.
7. European Medicines Agency. Humira pre-filled pen, pre-filled syringe and vial: summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 15 Oct 2015.
8. Croom KF, McCormack PL. Adalimumab: in plaque psoriasis. Am J Clin Dermatol. 2009;10(1):43-50.
9. Johnson-Huang LM, McNutt NS, Krueger JG, et al. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol. 2009;29(3):247-56.
10. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149-60.
11. Gordon KB, Bonish BK, Patel T, et al. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005;153(5):945-53.
12. Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007;48(2):87-101.
13. Hendriks AG, van der Velden HM, Wolberink EA, et al. The effect of adalimumab on key drivers in the pathogenesis of psoriasis. Br J Dermatol. 2014;170(3):571-80.
14. Soegaard-Madsen L, Johansen C, Iversen L, et al. Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. Br J Dermatol. 2010;162(6):1216-23.
15. Johansen C, Vinter H, Soegaard-Madsen L, et al. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFalpha therapy. Br J Dermatol. 2010;163(6):1194-204.
16. Goldminz AM, Suarez-Farinas M, Wang AC, et al. CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial. JAMA Dermatol. 2015;151(8):837-46.
17. Strober BE, Poulin Y, Teller C, et al. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. J Eur Acad Dermatol Venereol. 2014;28(12):1701-6.
18. Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15(1):45-50.
19. Bissonnette R, Tardif JC, Harel F, et al. Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging. 2013;6(1):83-90.
20. Sharma S, Noertersheuser P, Mostafa N. Pharmacokinetics of adalimumab in adult patients with moderate to severe chronic plaque psoriasis [abstract no. P1662]. In: 23rd European Academy of Dermatology and Venereology (EADV) Congress. 2014.
21. Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507.
22. Papp K, Thaci D, Marcoux D. Efficacy and safety of adalimumab versus methotrexate treatment in pediatric patients with severe chronic plaque psoriasis: results from the 16-week randomized, double-blind period of a phase 3 study [abstract plus poster]. In: The 23rd World Congress of Dermatology. 2015.
23. Philipp S, Ghislain P-D, Landells I. Efficacy, safety of adalimumab vs methotrexate in pediatric patients with severe chronic plaque psoriasis: results from the treatment withdrawal and double-blind retreatment periods of a phase 3 study [abstract plus poster]. In: The 23rd World Congress of Dermatology. 2015.
24. European Medicines Agency. Extension of indication variation assessment report: procedure no. EMEA/H/C/000481/II/0134 2015. http://www.ema.europa.eu/. Accessed 15 Oct 2015.
25. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-15.
26. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-66.
27. Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol. 2011;12(1):51-62.
28. Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448-56.
29. Prussick R, Unnebrink K, Valdecantos WC. Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis. J Drugs Dermatol. 2015;14(8):864-8.
30. Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341-50.
31. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158(3):549-57.
32. Papp KA, Signorovitch J, Ramakrishnan K, et al. Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. Clin Drug Investig. 2011;31(1):51-60.
33. Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241-51.
34. Papp K, Menter A, Poulin Y, et al. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol. 2013;27(5):634-42.
35. Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011;164(2):434-41.
36. Poulin Y, Sheth P, Gu Y, et al. Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy. Dermatol Ther. 2014;4(1):33-42.
37. Gordon KB, Gottlieb AB, Langely RG, et al. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015;29(4):767-76.
38. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163(2):402-11.
39. Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429-36.
40. Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12(5):321-37.
41. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72(4):517-24.
42. Menter A, Thaci D, Papp KA, et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73(3):410-9 (e6).
43. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261-73.
44. Menting SP, van Lumig PP, de Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol. 2014;150(2):130-6.
45. Asahina A, Nakagawa H, Etoh T. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299-310.
46. Asahina A, Ohtsuki M, Etoh T, et al. Adalimumab treatment optimization for psoriasis: results of a long-term phase 2/3 Japanese study. J Dermatol. 2015;14(11):1042-52.
47. Lebrec H, Ponce R, Preston BD, et al. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin. 2015;31(3):557-74.
48. Farhangian ME, Feldman SR. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015;16(4):285-94.
49. Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):127-32.
50. Chiu HY, Wang TS, Chan CC, et al. Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis. Acta Derm Venereol. 2015;95(6):711-6.
51. Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28(4):438-53.
52. Bissonnette R, Bolduc C, Poulin Y, et al. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol. 2010;63(2):228-34.
53. Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64(4):671-81.
54. Sator P, Richter L, Saxinger W, et al. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics. J Eur Acad Dermatol Venereol. 2015;29(9):1742-9.
55. Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244-52.
56. Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632-40.
57. van den Reek JM, Zweegers J, Kievit W, et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol. 2014;171(5):1189-96.
58. van den Reek JM, Tummers M, Zweegers J, et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol. 2015;29(3):560-5.
59. Esposito M, Gisondi P, Cassano N, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666-72.
60. Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: report from the psoriasis registry Austria. Acta Derm Venereol. 2015. doi: 10.2340/00015555-2214.
61. Mustonen A, Mattila K, Leino M, et al. Psoriasis causes significant economic burden to patients. Dermatol Ther (Heidelb). 2014;4(1):115-24.
62. Fragoulakis V, Raptis E, Vitsou E, et al. Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece. Clinicoecon Outcomes Res. 2015;7:73-83.
63. Zhang W, Islam N, Ma C, et al. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015;33(4):327-40.
64. Ruano J, Isla-Tejera B, Jimenez-Puya R, et al. Long-term cost-effectiveness analysis of etanercept and adalimumab for plaque psoriasis not associated with arthritis. Dermatol Ther (Heidelb). 2013;3(2):131-42.
65. D'Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72(4):589-98.
66. Sawyer LM, Wonderling D, Jackson K, et al. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis. Pharmacoeconomics. 2015;33(2):163-77.
67. Chi CC, Wang SH. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle. Biomed Res Int. 2014;2014:862851.
68. Ahn CS, Gustafson CJ, Sandoval LF, et al. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14(4):315-26.
69. Ferrandiz C, Garcia A, Blasco AJ, et al. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2012;26(6):768-77.
70. Puig L, Lopez A, Vilarrasa E, et al. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol. 2014;28(12):1633-53.
71. Galvan-Banqueri M, Marin Gil R, Santos Ramos B, et al. Biological treatments for moderate-to-severe psoriasis: indirect comparison. J Clin Pharm Ther. 2013;38(2):121-30.
72. Reich K, Burden AD, Eaton JN, et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012;166(1):179-88.
73. Messori A, Fadda V, Maratea D, et al. Biological drugs for the treatment of moderate-to-severe psoriasis by subcutaneous route: determining statistical equivalence according to evidence-based methods. Clin Drug Investig. 2014;34(8):593-8.
74. Puig L. On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis. J Clin Pharm Ther. 2015;40(2):131-4.
75. Feldman SR. Factors for choosing the right biologic treatment. The Dermatologist. 2014;22(9). http://www.the-dermatologist.com/content/factors-choosing-right-biologic-treatment. Accessed 13 Jul 2015.